Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities.

Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities.
复制标题

在美国青少年少数群体中发现的交叉反应性 CD8 T 细胞表位。

DOI:
10.1097/00126334-200308010-00003
复制
发表时间:
2003
期刊:
Journal of acquired immune deficiency syndromes (1999)
影响因子:
--
通讯作者:
Goepfert,PaulA
Goepfert,PaulA
中科院分区:
--
文献类型:
--
作者:
Sabbaj,Steffanie;Bansal,Anju;Ritter,GDouglas;Perkins,Christopher;Edwards,BradleyH;Gough,Ethan;Tang,Jianming;Szinger,JamesJ;Korber,Bette;Wilson,CraigM;Kaslow,RichardA;Mulligan,MarkJ;Goepfert,PaulA

文献摘要

被引文献

相似文献

设计用于在不同种族和民族群体中产生CD 8 + T细胞应答的疫苗将需要包含由各种MHC I类分子呈递的T细胞表位。本研究旨在确定新的CD 8 + T细胞表位在艾滋病毒感染的非洲裔美国人和西班牙裔青年,以及确定响应的频率在一个队列中的新的和以前描述的HIV-1表位的种族和民族多样化的个人。我们发现了8个以前没有描述过的MHC I类限制性CD 8 + T细胞表位,另外8个表位被以前没有与这些表位相关的I类等位基因限制,以及8个以前已经描述过的额外表位。在一个更大的队列中,我们证明了这16种新描述的免疫原中有11种(69%)被不同种族或民族的个体识别。大多数HIV-1特异性CD 8 + T细胞表位是新的或受替代MHC I类等位基因的限制。在不同种族背景的人中频繁识别这些CTL表位中的几个预示着广泛反应性HIV-1疫苗的发展。
: Vaccines designed to bring forth CD8+ T cell responses in different racial and ethnic groups will require inclusion of T cell epitopes presented by various MHC class I molecules. This study was designed to identify new CD8+ T cell epitopes in HIV-infected African American and Hispanic youth as well as to determine the frequency of responses to both novel and previously described HIV-1 epitopes in a cohort of racially and ethnically diverse individuals. We found 8 MHC class I-restricted CD8+ T cell epitopes that had not been previously described, another 8 epitopes that were restricted by class I alleles not previously associated with these epitopes, and 8 additional epitopes that have been described previously. In a larger cohort, we demonstrated that 11 (69%) of these 16 newly described immunogens were recognized by individuals of different race or ethnicity. Most HIV-1-specific CD8+ T cell epitopes identified were either novel or restricted by alternative MHC class I alleles. Frequent recognition of several of these CTL epitopes in persons of diverse racial backgrounds bodes well for the development of a broadly reactive HIV-1 vaccine.